Navigation Links
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
Date:7/23/2013

currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the potential for the results of ongoing clinical trials to support further development, regulatory approval or the marketing success of ARRY-502, and future plans to progress, develop and partner ARRY-502. These statements involve significant risks and uncertainties, including those discussed in the most recent annual report filed on form 10-K, quarterly reports filed on Form 10-Q, and other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect current expectations concerning future events, actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, the ability o
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Enterprise Europe Network - Sport Meets Business: How Entrepreneurs Beat the Recession
3. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
4. Omnetics Meets Increasing Demands of Miniature Electronics Industry with Custom Designed Micro and Nano Cables
5. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
6. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
7. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
10. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
11. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... Financing Provides Capital to Complete EVEREST Pivotal Study and Begin ... European Commercialization ... Investors, MENLO PARK, Calif., Dec. 4 Evalve, Inc., the leader ... that it had successfully completed a $60 million Series D,financing. BBT Fund ...
... Bivalirudin lowers bleeding risk for patients undergoing bypass, study ... newer kind of anticlotting drug is safe over the ... heart attacks. , The drug, a "direct thrombin inhibitor" ... during cardiac procedures such as bypass surgery. , "We ...
... some truth to the popular wisdom that plump babies are ... people who had a low birth weight are more likely ... found that even people who had just mild or moderate ... smaller babies than those who had better mental health, said ...
... of New Orleans residents in months after the disaster, study ... the people living in New Orleans and about one-quarter of ... signs of a mood or anxiety disorder five to seven ... Researchers surveyed 1,043 residents in Louisiana, Alabama and Mississippi. , ...
... TARRYTOWN, N.Y., Dec. 4 EpiCept Corporation,(Nasdaq and OMX ... offering of 3,333,333 million shares of its common stock ... to approximately 1,666,667,million shares of common stock at an ... $4.7 million in net proceeds from the,offering. Rodman & ...
... Nabi,Biopharmaceuticals (Nasdaq: NABI ) announced ... assets constituting its Biologics strategic business unit ... of Biotest,AG, for $185 million in cash. ... has acquired or will acquire the Biologics ...
Cached Medicine News:Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 2Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 3Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 3Health News:Smaller babies more prone to depression, anxiety later on 2Health News:Many Katrina Survivors Suffered Psychological Symptoms 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 2Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 3
... & Nephew offers a wide variety of ... available in both partially threaded and fully ... are the 5.5 and 7.0 mm products. ... the surgeon's job a little easier. Ratchet ...
... Nailing System is one of the first ... for either an antegrade or a retrograde ... , ,Stryker Orthopaedics Trauma has now created ... together all the capabilities and benefits of ...
... Humeral Nail System has been designed to ... noninvasive treatments have historically failed to give ... blend of strength and flexibility. Ideally suited ... titanium alloy is twice that of stainless ...
... nailing techniques have largely replaced the use of plates ... The use of rods or pins in the forearm ... has been no way to lock the pins or ... a non-locked nail is back out of the implant. ...
Medicine Products: